Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment

International Journal of Pharmaceutics

Volumn 454, Issue 1, 2013, Pages 435-443

  Larson, Nate ^a,b   Yang, Jiyuan ^b   Ray, Abhijit ^a,b   Cheney, Darwin L ^a,b   Ghandehari, Hamidreza ^b,c   Kopeček, Jindřich ^b,c  

^a TheraTarget   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c Department of Electrical and Computer Engineering   (United States)

Author keywords

Biodegradable polymers; Combination therapy; Gemcitabine; HPMA copolymers; Ovarian cancer; Paclitaxel

Indexed keywords

CATHEPSIN B; COPOLYMER; GEMCITABINE; PACLITAXEL; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE];

ARTICLE; BIODEGRADABILITY; CANCER CELL; DRUG ANTAGONISM; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG HYDROLYSIS; DRUG POTENTIATION; DRUG RELEASE; DRUG SCREENING; DRUG SENSITIVITY; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR WEIGHT; OVARY CANCER; PH; POLYMERIZATION; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 84884132243     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.06.046     Document Type: Article

References (50)

1. Bookman, M.A., 2010. The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer. Ann. Oncol. 21 (Suppl. 7), vii211-vii217.
2. Chipman, S.D., Oldham, F.B., Pezzoni, G., Singer, J.W., 2006. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int. J. Nanomed. 1, 375-383.
3. Chou, T.C., Talalay, P., 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55.
4. Dumontet, C., Sikic, B.I., 1999. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 17, 1061-1070. (Pubitemid 29109340)
5. Duncan, R., Coatsworth, J.K., Burtles, S., 1998. Preclinical toxicology of a novel polymeric antitumour agent HPMA copolymer-doxorubicin (PK1). Hum. Exp. Toxicol. 17, 93-104. (Pubitemid 28076000)
6. Duncan, R., Vicent, M.J., 2010. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv. Drug Deliv. Rev. 62, 272-282.
7. Friedlander, M., Buck, M., Wyld, D., Findlay, M., Fitzharris, B., De Souza, P., Davies, T., Kalimi, G., Allan, S., Perez, D., Harnett, P., 2007. Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer. Int. J. Gynecol. Cancer 17, 350-358. (Pubitemid 46426766)
8. Gallo, D., Fruscella, E., Ferlini, C., Apollonio, P., Mancuso, S., Scambia, G., 2006. Preclinical in vivo activity of a combination gemcitabine/liposomal doxorubicin against cisplatin-resistant human ovarian cancer (A2780/CDDP). Int. J. Gynecol. Cancer 16, 222-230.
9. Garcia, A.A., Yessaian, A., Pham, H., Facio, G., Muderspach, L., Roman, L., 2012. Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer. Cancer Invest. 30, 295-299.
10. Heinemann, V., Xu, Y.Z., Chubb, S., Sen, A., Hertel, L.W., Grindey, G.B., Plunkett, W., 1992. Cellular elimination of 2′,2′- difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res. 52, 533-539.
11. Hendrickson, A.E., Oberg, A.L., Glaser, G., Camoriano, J.K., Peethambaram, P.P., Colon-Otero, G., Erlichman, C., Ivy, S.P., Kaufmann, S.H., Karnitz, L.M., Haluska, P., 2012. A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. Gynecol. Oncol. 124, 210-215.
12. Herzog, T.J., 2006. The current treatment of recurrent ovarian cancer. Curr. Oncol. Rep. 8, 448-454. (Pubitemid 44697774)
13. Herzog, T.J., Pothuri, B., 2006. Ovarian cancer: a focus on management of recurrent disease. Nat. Clin. Pract. Oncol. 3, 604-611. (Pubitemid 44669715)
14. Hongrapipat, J., Kopečková, P., Liu, J., Prakongpan, S., Kopeček, J., 2008. Combination chemotherapy and photodynamic therapy with Fab′ fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells. Mol. Pharm. 5, 696-709.
15. Kiew, L.V., Cheong, S.K., Sidik, K., Chung, L.Y., 2010. Improved plasma stability and sustained release profile of gemcitabine via polypeptide conjugation. Int. J. Pharm. 391, 212-220.
16. Kim, A., Ueda, Y., Naka, T., Enomoto, T., 2012. Therapeutic strategies in epithelial ovarian cancer. J. Exp. Clin. Cancer Res. 31, 14.
17. Kopeček, J., 1977. Soluble biomedical polymers. Polim. Med. 7, 191-221.
18. Kopeček, J., 1990. The potential of water-soluble polymeric carriers in targeted and site-specific drug delivery. J. Control. Release 61, 145-157.
19. Kopeček, J., 2013. Polymer-drug conjugates: origins, progress to date and future directions. Adv. Drug Deliv. Rev. 65, 49-59.
20. Kopeček, J., Bažilová, H., 1973. Poly[N-(2-hydroxypropyl)methacrylamide]. 1. Radical polymerization and copolymerization. Eur. Polym. J. 9, 7-14.
21. Kopeček, J., Kopečková, P., 2010. HPMA copolymers: origins early developments, present, and future. Adv. Drug Deliv. Rev. 62, 122-149.
22. Kopeček, J., Kopečková, P., 2012. Design of polymer-drug conjugates. In: Kratz, F., Senter, P., Steinhagen, H. (Eds.), Drug Delivery in Oncology, Vol. 2, Chapter 17. Wiley-VCH, Weinheim, Germany, pp. 485-512.
23. Lammers, T., Šubr, V., Peschke, P., Kuhnlein, R., Hennink, W.E., Ulbrich, K., Kiessling, F., Heilmann, M., Debus, J., Huber, P.E., Storm, G., 2008. Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br. J. Cancer 99, 900-910.
24. Lammers, T., Šubr, V., Ulbrich, K., Peschke, P., Huber, P.E., Hennink, W.E., Storm, G., 2009. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 30, 3466-3475.
25. Lammers, T., Ulbrich, K., 2010. HPMA copolymers: 30 years of advances. Adv. Drug Deliv. Rev. 62, 119-121.
26. Larson, N., Ghandehari, H., 2012. Polymeric conjugates for drug delivery. Chem. Mater. 24, 840-853.
27. Liu, J., Kopečková, P., Bühler, P., Wolf, P., Pan, H., Bauer, H., Elsasser-Beile, U., Kopeček, J., 2009. Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells. Mol. Pharm. 6, 959-970.
28. Luo, K., Yang, J., Kopečková, P., Kopeček, J., 2011. Biodegradable multi-block poly[N-(2-hydroxypropyl)methacrylamide] via reversible additionfragmentation chain transfer polymerization and click chemistry. Macromolecules 44, 2481-2488.
29. Maeda, H., 2012. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J. Control. Release 164, 138-144.
30. Matsumura, Y., Maeda, H., 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46, 6387-6392. (Pubitemid 17221789)
31. Meerum Terwogt, J.M., Ten Bokkel Huinink, W.W., Schellens, J.H., Schot, M., Mandjes, I.A., Zurlo, M.G., Rocchetti, M., Rosing, H., Koopman, F.J., Beijnen, J.H., 2001. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 12, 315-323. (Pubitemid 32453436)
32. Mitsukami, Y., Donovan, M.S., Lowe, A.B., McCormick, C.L., 2001. Water-soluble polymers. 81. Direct synthesis of hydrophilic styrenic-based homopolymers and block copolymers in aqueous solution via RAFT. Macromolecules 34, 2248-2256. (Pubitemid 34216797)
33. Mould, T., 2012. An overview of current diagnosis and treatment in ovarian cancer. Int. J. Gynecol. Cancer 22 (Suppl. 1), S2-S4.
34. Naumann, R.W., Coleman, R.L., 2011. Management strategies for recurrent platinumresistant ovarian cancer. Drugs 71, 1397-1412.
35. Oliveras-Ferraros, C., Vazquez-Martin, A., Colomer, R., De Llorens, R., Brunet, J., Menendez, J.A., 2008. Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling. Int. J. Oncol. 32, 113-120. (Pubitemid 351176068)
36. Pan, H., Yang, J., Kopečková, P., Luo, K., Kopeček, J., 2011a. Polymeric drug delivery conjugates and methods of making and using thereof. WO Patent WO/2011/112,482.
37. Pan, H., Yang, J., Kopečková, P., Kopeček, J., 2011b. Backbone degradable multiblock N-(2-hydroxypropyl)methacrylamide copolymer conjugates via reversible addition-fragmentation chain transfer polymerization and thiol-ene coupling reaction. Biomacromolecules 12, 247-252.
38. Pan, H., Sima, M., Yang, J., Kopeček, J., 2013. Synthesis of long-circulating backbone degradable HPMA copolymer-doxorubicin conjugates and evaluation of molecular weight dependent antitumor efficacy. Macromol. Biosci. 13, 155-160.
39. Peters, G.J., Ruiz Van Haperen, V.W., Bergman, A.M., Veerman, G., Smitskamp-Wilms, E., Van Moorsel, C.J., Kuiper, C.M., Braakhuis, B.J., 1996. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin. Oncol. 23, 16-24. (Pubitemid 26362190)
40. Rowinsky, E.K., Eisenhauer, E.A., Chaudhry, V., Arbuck, S.G., Donehower, R.C., 1993. Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol. 20, 1-15. (Pubitemid 23239390)
41. Seymour, L.W., Ferry, D.R., Kerr, D.J., Rea, D., Whitlock, M., Poyner, R., Boivin, C., Hesslewood, S., Twelves, C., Blackie, R., Schatzlein, A., Jodrell, D., Bissett, D., Calvert, H., Lind, M., Robbins, A., Burtles, S., Duncan, R., Cassidy, J., 2009. Phase II studies of polymer-doxorubicin (PK1 FCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol. 34, 1629-1636.
42. Sui, M., Xiong, X., Kraft, A.S., Fan, W., 2006. Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis. Cancer Biol. Ther. 5, 1015-1021.
43. Thomson, A.H., Vasey, P.A., Murray, L.S., Cassidy, J., Fraier, D., Frigerio, E., Twelves, C., 1999. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. Br. J. Cancer 81, 99-107. (Pubitemid 29415498)
44. Touma, R., Kartarius, S., Harlozinska, A., Gotz, C., Montenarh, M., 2006. Growth inhibition and apoptosis induction in ovarian cancer cells. Int. J. Oncol. 29, 481-488.
45. Vicent, M.J., Ringsdorf, H., Duncan, R., 2009. Polymer therapeutics: clinical applications and challenges for development. Adv. Drug Deliv. Rev. 61, 1117-1120.
46. Wakabayashi, M.T., Lin, P.S., Hakim, A.A., 2008. The role of cytoreductive/debulking surgery in ovarian cancer. J. Natl. Compr. Canc. Netw. 6, 803-810.
47. Weiss, R.B., Donehower, R.C., Wiernik, P.H., Ohnuma, T., Gralla, R.J., Trump, D.L., Baker Jr., J.R., Van Echo, D.A., Von Hoff, D.D., Leyland-Jones, B., 1990. Hypersensitivity reactions from taxol. J. Clin. Oncol. 8, 1263-1268. (Pubitemid 20195638)
48. Yang, J., Luo, K., Pan, H., Kopečková, P., Kopeček, J., 2011. Synthesis of biodegradable multiblock copolymers by click coupling of RAFT-generated heterotelechelic polyHPMA conjugates. React. Funct. Polym. 71, 294-302.
49. Zhang, R., Luo, K., Yang, J., Sima, M., Sun, Y., Janat-Amsbury, M., Kopeček, J., 2013. Synthesis and evaluation of a backbone degradable multiblock HPMA copolymer nanocarriers for delivery of paclitaxel. J. Control. Release 166, 66-74.
50. Zupi, G., Scarsella, M., D'angelo, C., Biroccio, A., Paoletti, G., Lopez, M., Leonetti, C., 2005. Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. Cancer Biol. Ther. 4, 866-871.